Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
April 17, 2019
Date of Patent:
February 11, 2020
Assignee:
NOVALIQ GMBH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: A pharmaceutical composition for promoting nerve injury restoration and a use thereof are disclosed. Each unit of the pharmaceutical composition contains 0.5 to 8 g of L-ornithine, 1 to 5 g of aspartic acid, 3 to 10 g of arginine and 3 to 10 g of vitamin B6. The pharmaceutical composition can significantly promote recovery of the spinal nerve function, and particularly has a good therapeutic effect on acute myelitis.
Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
June 25, 2018
Date of Patent:
January 7, 2020
Assignee:
NOVALIQ GMBH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: A filler material of a thermoset resin of a diacid/polyol, such as PGS is provided. The filler useful in forming composites, such as those in which the filler and a resin matrix are of the same material to provide a homogenous polymeric composition. Composites in which at least one of the matrix, the filler or both are PGS are also provided. Methods of forming such filler materials and composites are also disclosed. The composites allow extrusion process to form articles from materials that would not otherwise be capable of being extruded.
Type:
Grant
Filed:
February 24, 2017
Date of Patent:
January 7, 2020
Assignee:
THE SECANT GROUP, LLC
Inventors:
Kayla Wroblesky, Carissa Smoot, Peter D. Gabriele, Jeremy J. Harris, Charles Brendan Nicholson, Steven Lu
Abstract: The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.
Abstract: The present invention includes a method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or FLT3 tyrosine kinase expression in a subject with a proliferative disease by administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound (CP-673,451) of Formula I: or pharmaceutically acceptable salt thereof.
Abstract: Provided are a cosmetic composition for anti-aging or alleviating skin redness, and a medicinal composition for treating and preventing skin inflammatory diseases caused by light, containing a compound inducing an increase in expression of adiponectin or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
April 20, 2018
Date of Patent:
November 5, 2019
Assignee:
Incospharm Corporation
Inventors:
Kee Don Park, Hwa-Jee Chung, Heung Jae Kim, Chae Jin Lim, Seok Jeong Yoon, Jong Phill Kang, Seon Deok Kwon, Myung Ho Kor, Ju Yeon Jung, Beom Cheol Kim, Ka Young Shin
Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Abstract: Methods and compositions which include or include the administration of a hydrophobic drug, prodrug thereof, salt thereof, isoform thereof, or a combination thereof; cyclodextrin, prodrug thereof, salt thereof, or a combination thereof; polyethylene glycol, propylene glycol, or combination thereof; and optionally, a pharmaceutically acceptable carrier.
Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
January 18, 2018
Date of Patent:
September 10, 2019
Assignees:
CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
Abstract: This invention relates to the treatment of varying degrees of cognitive impairment associated with, for example, aging, Alzheimer's disease, schizophrenia with low dose administration of a PDE4 inhibitor, specifically roflumilast.
Type:
Grant
Filed:
August 15, 2014
Date of Patent:
July 23, 2019
Assignee:
UNIVERSITEIT MAASTRICHT
Inventors:
Jos Prickaerts, Marlies van Duinen, Anke Sambeth, Arjan Blokland
Abstract: This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic
Type:
Grant
Filed:
February 15, 2017
Date of Patent:
July 16, 2019
Assignee:
SK Biopharmaceuticals Co., Ltd.
Inventors:
Abdallah Ahnaou, Wilhelmus H. I. M. Drinkenburg, Joseph Palumbo, Jonathan Sporn
Abstract: Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain.
Type:
Grant
Filed:
July 2, 2007
Date of Patent:
July 2, 2019
Assignees:
Sloan-Kettering Institute for Cancer Research, The Rockefeller University
Abstract: Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ArfGAP1, inhibition that counteracts the deleterious effects of mutations in, or increased expression of, the LRRK2 protein.
Type:
Grant
Filed:
April 10, 2015
Date of Patent:
May 28, 2019
Assignee:
DALHOUSIE UNIVERSITY
Inventors:
Michel Roberge, Chris McMaster, Carla Zimmerman, Pak Poon
Abstract: The present invention includes compositions and methods for using a single pharmaceutical preparation of KMgCit is a convenient surrogate or to support the DASH diet in lowering blood pressure among patients with essential hypertension. Support is provided by potassium, magnesium and alkali, which overcome the underlying physiological-biochemical disturbances of essential hypertension, such as salt sensitivity, insulin resistance, low urinary pH, low serum magnesium and renal leak of calcium. Positive effects of KMgCitrate disclosed in normal subjects and patients with stones, provides assurance that KMgCitrate should ameliorate the above physiological-biochemical disturbances and associated disorders in patients with essential hypertension.
Type:
Grant
Filed:
February 9, 2007
Date of Patent:
April 9, 2019
Assignee:
Board of Regents, the University of Texas System
Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
Abstract: The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family member pathways and DNA damage response pathways with the small molecules.
Abstract: Compound of formula X wherein P1 is a fused-ring system comprising one 6-membered and two 5-membered rings; v indicates an S or R configuration; or individual isomers or pharmaceutically acceptable salts thereof, or mixtures thereof, in the preparation of an active agent for preventing or inhibiting cell proliferation or for inducing cell death.
Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, and the like.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
February 19, 2019
Assignee:
Celgene Quanticel Research, Inc.
Inventors:
Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace